Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20936684 | 0.85 | ALDH1A1 (0.40) | ALDH1A1GAATSHRNPC1RAB9A | |
| SCHEMBL21362360 | 0.82 | GLA (0.39) | ALDH1A1GAATSHRNPC1RAB9A | |
| SCHEMBL15865519 | 0.80 | TSHR (0.36) | ALDH1A1GAATSHR | |
| SCHEMBL19872340 | 0.80 | TSHR (0.36) | ALDH1A1GAATSHR | |
| SCHEMBL1250453 | 0.80 | ALDH1A1 (0.45) | ALDH1A1GAATSHRNPC1RAB9A | |
| SCHEMBL1666704 | 0.80 | ALDH1A1 (0.45) | ALDH1A1GAATSHRNPC1RAB9A | |
| SCHEMBL19856419 | 0.80 | ALDH1A1 (0.45) | ALDH1A1GAATSHRNPC1RAB9A | |
| SCHEMBL19856434 | 0.80 | ALDH1A1 (0.45) | ALDH1A1GAATSHRNPC1RAB9A | |
| SCHEMBL1250455 | 0.80 | ALDH1A1 (0.45) | ALDH1A1GAATSHRNPC1RAB9A | |
| SCHEMBL1250452 | 0.80 | ALDH1A1 (0.45) | ALDH1A1GAATSHRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300926-A1 | NEW BETA-LACTAMASE INHIBITORS TARGETING GRAM NEGATIVE BACTERIA | UNIVERSITÉ PARIS CITÉ (FR) | 2021-09-30 | — | — | US | disclosed |
| US-20200325139-A1 | NEW ANTIBIOTICS TARGETING MYCOBACTERIA | UNIVERSITÉ PARIS CITÉ (FR) | 2020-10-15 | — | — | US | disclosed |
| US-9676777-B2 | Compounds useful for producing an optically active diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-20160137645-A1 | COMPOUNDS USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-9284273-B2 | Compounds useful for producing an optically active diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-03-15 | — | — | US | disclosed |
| US-20150239840-A1 | COMPOUNDS USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9035062-B2 | Process for preparing a compound useful for producing an optically active diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-19 | — | — | US | disclosed |
| US-20140303375-A1 | PROCESS FOR PREPARING A COMPOUND USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND | Meiji Seika Pharma. Co., Ltd. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8772490-B2 | Optically active diazabicyclooctane derivatives and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20120165533-A1 | OPTICALLY ACTIVE DIAZABICYCLOOCTANE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325139-A1 | NEW ANTIBIOTICS TARGETING MYCOBACTERIA | MAGT1, RPN2, MAFG | ALDH1A1 4334/4885GAA 58/4885TSHR 3834/4885 |
| US-20210300926-A1 | NEW BETA-LACTAMASE INHIBITORS TARGETING GRAM NEGATIVE BACTERIA | LCT, MGAM, PGLS | ALDH1A1 2390/4885GAA 4/4885TSHR 4777/4885 |
| US-20120165533-A1 | OPTICALLY ACTIVE DIAZABICYCLOOCTANE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | DCXR, CBR1, DECR1 | ALDH1A1 1488/4885GAA 226/4885TSHR 303/4885 |
| US-20140303375-A1 | PROCESS FOR PREPARING A COMPOUND USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND | TBC1D15, TBC1D5, TERT | ALDH1A1 505/4885GAA 1108/4885TSHR 450/4885 |
| US-20160137645-A1 | COMPOUNDS USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND | CBR1, CBR3, DOHH | ALDH1A1 594/4885GAA 1895/4885TSHR 1104/4885 |
| US-20150239840-A1 | COMPOUNDS USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND | TERT, TBC1D5, TBC1D15 | ALDH1A1 1067/4885GAA 738/4885TSHR 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.